ARTICLE | Company News
Lilly, AC Immune to develop tau inhibitors
December 12, 2018 11:30 AM UTC
Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which is in preclinical testing.
Lilly will pay AC Immune CHF80 million ($81 million) up front and purchase a $50 million note, convertible at a premium. The biotech is also eligible for CHF60 million ($60.1 million) in near-term milestones and up to CHF1.7 billion ($1.7 billion) in additional milestones, plus low double-digit tiered royalties...